Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of hematologic diseases through innovative therapies. The company is primarily focused on manipulating the hepcidin pathway, which is the master regulator of iron metabolism, to address ineffective red blood cell production in various hematologic conditions. By leveraging new insights into hepcidin biology, Disc Medicine strives to bring hope and improved quality of life to patients who suffer from serious blood disorders.
Disc Medicine is currently advancing several first-in-class therapeutic candidates that target fundamental red blood cell biology pathways, including heme biosynthesis and iron homeostasis. Among its leading candidates is DISC-0974, an investigational monoclonal antibody designed to suppress hepcidin production by inhibiting the hemojuvelin (HJV) co-receptor. This novel treatment has shown promising results in reducing serum hepcidin and increasing serum iron levels, leading to improvements in hemoglobin and reduced transfusion burdens in myelofibrosis (MF) patients with anemia.
The company also boasts bitopertin, an orally administered GlyT1 inhibitor that modulates heme biosynthesis. Bitopertin has demonstrated significant efficacy in reducing PPIX levels and improving sunlight tolerance in patients with erythropoietic protoporphyria (EPP) during the phase 2 BEACON study. Disc Medicine is actively working on further trials to solidify these findings and expand its therapeutic applications.
On the financial front, Disc Medicine is well-supported by a robust pipeline of both clinical and preclinical candidates aimed at transforming the landscape of hematologic treatments. Recently, the company presented compelling data at the 65th American Society of Hematology (ASH) Annual Meeting, showcasing the potential of its portfolio. Their commitment to advancing these therapies is evident from their ongoing and upcoming clinical trials, including the phase 1b/2a study of DISC-0974 in chronic kidney disease (CKD) patients with anemia and the phase 1 study of DISC-3405 in healthy volunteers.
Disc Medicine continues to foster strategic partnerships and collaborations to accelerate the development and commercialization of its products. The company's vision is to address unmet medical needs in hematology and deliver innovative therapies that can change the standard of care for patients globally.
Disc Medicine (NASDAQ:IRON) reported its Q4 and full year 2024 financial results, highlighting significant progress across its pipeline. The company ended 2024 with $490 million in cash and secured additional funding through a January 2025 public offering, extending operations into 2028.
Key developments include plans for bitopertin NDA submission in H2 2025 for erythropoietic protoporphyria (EPP) through accelerated approval pathway, with the APOLLO confirmatory trial set to begin mid-2025. The company presented positive data from DISC-0974's Phase 1b trial in myelofibrosis anemia and non-dialysis-dependent chronic kidney disease patients.
Financial results show R&D expenses increased to $96.7 million in 2024 from $69.3 million in 2023, while net loss widened to $109.4 million from $76.4 million. SG&A expenses rose to $33.0 million from $21.9 million, reflecting increased headcount and commercialization preparation efforts.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in hematologic disease treatments, has announced its participation in four major upcoming investor conferences in March 2025.
The company will deliver presentations at:
- TD Cowen 45th Annual Health Care Conference in Boston (March 5th, 9:10 a.m. ET)
- Leerink Global Healthcare Conference in Miami (March 10th, 2:20 p.m. ET)
- Barclays 27th Annual Global Healthcare Conference in Miami (March 13th, 9:30 a.m. ET)
- Jefferies Biotech on the Beach Summit in Miami (March 11th)
Live webcasts of the presentations and fireside chats will be accessible through Disc Medicine's investor relations website, with archived replays available post-event.
Disc Medicine (NASDAQ: IRON) has announced the pricing of its upsized public offering, consisting of 3,918,182 shares of common stock at $55.00 per share and pre-funded warrants to purchase 181,818 shares at $54.9999 per warrant. The offering is expected to generate approximately $225.5 million in gross proceeds before deducting expenses.
The company has granted underwriters a 30-day option to purchase up to an additional $33.825 million of shares. The offering is expected to close on January 24, 2025. Proceeds will fund research and clinical development, support potential commercialization of bitopertin for EPP and XLP, and provide working capital.
Jefferies, Leerink Partners, Stifel, and Cantor are serving as joint book-running managers, with BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, and H.C. Wainwright & Co. as co-managers.
Disc Medicine (NASDAQ: IRON) has announced a proposed public offering of $200.0 million of common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to an additional $30.0 million of shares. The proceeds will fund research and clinical development of product candidates, support potential commercialization of bitopertin for EPP and XLP, and provide working capital.
The offering is being managed by joint book-runners Jefferies, Leerink Partners, Stifel, and Cantor. The securities will be offered through an automatic shelf registration statement previously filed with the SEC. The completion, size, and terms of the offering are subject to market conditions.
Disc Medicine (NASDAQ:IRON) has received positive feedback from its Type C meeting with the FDA regarding bitopertin for Erythropoietic Protoporphyria (EPP) treatment. The company plans to submit a New Drug Application (NDA) in H2 2025 under the accelerated approval pathway, using protoporphyrin IX (PPIX) reduction as the surrogate endpoint.
The FDA meeting resulted in alignment on the APOLLO post-marketing confirmatory trial design, set to begin by mid-2025. The trial will feature co-primary endpoints: average monthly time in sunlight without pain and percent change in whole blood metal-free PPIX after 6 months of treatment. The study will be double-blind, placebo-controlled with approximately 150 patients aged 12+ randomized 1:1, including sites in the US, Canada, Europe, and Australia.
Disc Medicine (NASDAQ:IRON) has announced a conference call scheduled for Tuesday, January 21, at 8:00 am EST to discuss feedback from its Type C meeting with the FDA regarding bitopertin in Erythropoietic Protoporphyria (EPP). The company, which focuses on developing treatments for serious hematologic diseases, will host the discussion to share insights from their regulatory interaction.
Interested participants can register for the event through the Events and Presentations section of Disc Medicine's investor relations website. This meeting represents a significant step in the development process for bitopertin as a potential treatment for EPP patients.
Disc Medicine (NASDAQ:IRON) has announced an inducement equity award for a new employee, effective January 16, 2025. The award consists of two components: (1) an option to purchase 35,000 shares of common stock at the January 16, 2025 closing price, and (2) a restricted stock unit (RSU) award for 23,333 shares.
The stock option has a ten-year term with 25% vesting on January 16, 2026, and the remaining vesting monthly over 36 months. The RSU award vests in equal installments over four years. The Compensation Committee approved this award as an employment inducement under Nasdaq Rule 5635(c)(4), outside the company's regular stock incentive plan but under similar terms.
Disc Medicine (NASDAQ:IRON) outlined its achievements and strategic priorities for 2025, highlighting significant progress across its hematology portfolio. Following positive phase 2 results for bitopertin in EPP, the company will discuss NDA submission plans under potential accelerated approval in Q1 2025.
Key upcoming milestones include initial data from phase 2 study of DISC-0974 in myelofibrosis anemia and higher dose data from phase 1b study in CKD anemia, both expected H2 2025. The company plans to initiate a phase 2 study of DISC-3405 in polycythemia vera in H1 2025.
The company strengthened its balance sheet through a $178 million equity offering and secured debt facility, providing cash runway into 2027. 2024 achievements included positive FDA end-of-phase 2 meeting for bitopertin, successful phase 2 AURORA and BEACON studies, and encouraging results from DISC-0974 trials.
Disc Medicine (NASDAQ:IRON) presented positive clinical data across its portfolio at the ASH 2024 Annual Meeting, featuring 8 posters and complete results from multiple trials. Key highlights include:
- Updates from BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP) showing significant PPIX reduction and improved sunlight tolerance
- Complete results from Phase 1b trial of DISC-0974 in myelofibrosis anemia, supporting advancement to Phase 2
- Phase 1 SAD/MAD trial data of DISC-3405 in healthy volunteers demonstrating sustained serum iron reduction and good tolerability
The company also presented preclinical data supporting potential expansion into new indications and a real-world patient survey highlighting EPP disease burden.
Disc Medicine (NASDAQ:IRON) presented positive updated results from its Phase 1b trial of DISC-0974 in patients with myelofibrosis (MF) and anemia at the 2024 ASH annual meeting. The trial enrolled 35 adult patients across different transfusion dependency groups and demonstrated significant clinical benefits.
Key results include: 68% of non-transfusion dependent patients achieved hemoglobin increase ≥1.5 g/dL; 100% of low transfusion dependent patients achieved ≥50% reduction in transfusion needs, with 80% reaching transfusion independence; 60% of high transfusion dependent patients achieved ≥50% reduction in requirements, with 40% reaching independence. The treatment showed >75% reduction in hepcidin across patients.
DISC-0974 was generally well-tolerated, with diarrhea being the only related adverse event reported in multiple subjects. The company has initiated a Phase 2 study following these positive results.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
What is Disc Medicine, Inc. focused on?
What is DISC-0974?
What are the recent achievements of Disc Medicine?
What is bitopertin?
What are the main research areas of Disc Medicine?
Who are the targeted patients for DISC-0974?
What does the phase 1b/2a study of DISC-0974 involve?
How does Disc Medicine plan to advance its therapies?
What is the significance of hepcidin in hematologic diseases?
How can I get more information about Disc Medicine's updates?
